The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Neznanov N.G.
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
First Pavlov State Medical University
Bogolepova A.N.
Pirogov Russian National Research Medical University (Pirogov University);
Federal Center for Brain and Neurotechnology
Vasilieva A.V.
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
Mechnikov Northwestern State Medical University
Zakharov V.V.
Sechenov First Moscow State Medical University (Sechenov University)
Lebedeva A.V.
Pirogov Russian National Research Medical University (Pirogov University);
Federal Center for Brain and Neurotechnology
Medvedev V.E.
Peoples’ Friendship University of Russia named after Patrice Lumumba
Solovieva E.Yu.
Pirogov Russian National Research Medical University (Pirogov University)
Tabeeva G.R.
Sechenov First Moscow State Medical University (Sechenov University)
Comorbid anxiety disorders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment strategy
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12): 126‑136
Views: 922
Downloaded: 4
To cite this article:
Neznanov NG, Tanashyan MM, Akarachkova ES, et al. . Comorbid anxiety disorders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment strategy. S.S. Korsakov Journal of Neurology and Psychiatry.
2024;124(12):126‑136. (In Russ.)
https://doi.org/10.17116/jnevro2024124121126
The article presents theses of the resolution of the Interdisciplinary Council of Experts in Psychiatry and Neurology (Moscow, 2024) on the issue of comorbid anxiety disorders (AD) in patients with neurological pathologies. The authors highlight the high prevalence of comorbid ADs and their significant negative impact on the course of underlying diseases, such as epilepsy, pain syndromes and post-stroke conditions. Modern approaches to the diagnosis and treatment of ADs in this group of patients are discussed. Special attention is given to the role of etifoxine as an effective anxiolytic in the comprehensive therapy of ADs. Etifoxine, due to its dual mechanism of action on GABA receptors, demonstrates high efficacy in reducing anxiety and has neuroprotective, neurotrophic, neuroplastic, analgesic, and anti-inflammatory properties, making it an important tool in the treatment of comorbid ADs in patients with neurological pathologies. The article also reviews recently published data confirming its efficacy and favourable safety profile compared to traditional benzodiazepines and other anxiolytic drugs.
Keywords:
Authors:
Neznanov N.G.
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
First Pavlov State Medical University
Bogolepova A.N.
Pirogov Russian National Research Medical University (Pirogov University);
Federal Center for Brain and Neurotechnology
Vasilieva A.V.
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
Mechnikov Northwestern State Medical University
Zakharov V.V.
Sechenov First Moscow State Medical University (Sechenov University)
Lebedeva A.V.
Pirogov Russian National Research Medical University (Pirogov University);
Federal Center for Brain and Neurotechnology
Medvedev V.E.
Peoples’ Friendship University of Russia named after Patrice Lumumba
Solovieva E.Yu.
Pirogov Russian National Research Medical University (Pirogov University)
Tabeeva G.R.
Sechenov First Moscow State Medical University (Sechenov University)
Received:
06.11.2024
Accepted:
29.11.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.